Ann: Advisor appointed to advance commercialisation in China, page-7

It looks like they have a cornerstone investor coming to help advance the pipeline. So, more dilution late in the year perhaps and maybe more preclinical work with that. The gene therapies and other attempts at HIV cures are still struggling for funds and there isn't a cure or vaccine imminent. Reservoirs being a major issue. Calimmune will be reporting on their four year old gene therapy trial soon......  the results are expected to be promising but no holy grail yet. Still room for HIV drugs that help the immune system. Probably worth averaging right down here, if you are a believer.